1
|
Durigutto P, Macor P, Pozzi N, Agostinis C, Bossi F, Meroni PL, Grossi C, Borghi MO, Planer W, Garred P, Tedesco F. Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I. THE JOURNAL OF IMMUNOLOGY 2020; 205:1385-1392. [PMID: 32759297 DOI: 10.4049/jimmunol.2000570] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 07/04/2020] [Indexed: 01/23/2023]
Abstract
β2-Glycoprotein I (β2-GPI) is an abundant plasma glycoprotein with unknown physiological function and is currently recognized as the main target of antiphospholipid Abs responsible for complement activation and vascular thrombosis in patients with antiphospholipid syndrome (APS). In this study, we provide evidence that mannose-binding lectin (MBL) binds to β2-GPI in Ca++ and a dose-dependent manner and that this interaction activates complement and promotes complement-dependent thrombin generation. Surprisingly, a significant binding was observed between MBL and isolated domains II and IV of β2-GPI, whereas the carbohydrate chains, domain I and domain V, were not involved in the interaction, documenting a noncanonical binding mode between MBL and β2-GPI. Importantly, this interaction may occur on endothelial cells because binding of MBL to β2-GPI was detected on the surface of HUVECs, and colocalization of MBL with β2-GPI was observed on the endothelium of a biopsy specimen of a femoral artery from an APS patient. Because β2-GPI-mediated MBL-dependent thrombin generation was increased after priming the endothelium with TNF-α, our data suggests that this mechanism could play an important yet unrecognized role under physiological conditions and may be upregulated in pathological situations. Moreover, the complement activation and the procoagulant effects of the β2-GPI/MBL complex may contribute to amplify similar activities of anti-β2-GPI Abs in APS and possibly act independently of Abs, raising the issue of developing appropriate therapies to avoid recurrences and disability in patients at risk for these clinical conditions.
Collapse
Affiliation(s)
- Paolo Durigutto
- Laboratorio di Immuno-Reumatologia, Istituto Auxologico Italiano, Istituto di Ricerca e Cura a Carattere Scientifico, Cusano Milanino, 20095 Milan, Italy
| | - Paolo Macor
- Department of Life Sciences, University of Trieste, 34127 Trieste, Italy
| | - Nicola Pozzi
- Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104
| | - Chiara Agostinis
- Istituto Materno-Infantile, Istituto di Ricerca e Cura a Carattere Scientifico, Burlo Garofolo, 34137 Trieste, Italy
| | - Fleur Bossi
- Istituto Materno-Infantile, Istituto di Ricerca e Cura a Carattere Scientifico, Burlo Garofolo, 34137 Trieste, Italy
| | - Pier Luigi Meroni
- Laboratorio di Immuno-Reumatologia, Istituto Auxologico Italiano, Istituto di Ricerca e Cura a Carattere Scientifico, Cusano Milanino, 20095 Milan, Italy
| | - Claudia Grossi
- Laboratorio di Immuno-Reumatologia, Istituto Auxologico Italiano, Istituto di Ricerca e Cura a Carattere Scientifico, Cusano Milanino, 20095 Milan, Italy
| | - Maria O Borghi
- Laboratorio di Immuno-Reumatologia, Istituto Auxologico Italiano, Istituto di Ricerca e Cura a Carattere Scientifico, Cusano Milanino, 20095 Milan, Italy.,Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; and
| | - William Planer
- Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104
| | - Peter Garred
- Laboratory of Molecular Medicine, Department of Clinical Immunology, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Francesco Tedesco
- Laboratorio di Immuno-Reumatologia, Istituto Auxologico Italiano, Istituto di Ricerca e Cura a Carattere Scientifico, Cusano Milanino, 20095 Milan, Italy;
| |
Collapse
|
2
|
Raschi E, Chighizola CB, Grossi C, Ronda N, Gatti R, Meroni PL, Borghi MO. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014; 55:42-50. [PMID: 24685231 DOI: 10.1016/j.jaut.2014.03.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Revised: 01/31/2014] [Accepted: 03/05/2014] [Indexed: 10/25/2022]
Abstract
The thrombogenic effect of β2-glycoprotein I (β2GPI)-dependent anti-phospholipid antibodies (aPL) in animal models was found to be LPS dependent. Since β2GPI behaves as LPS scavenger, LPS/β2GPI complex was suggested to account for in vitro cell activation through LPS/TLR4 involvement being LPS the actual bridge ligand between β2GPI and TLR4 at least in monocytes/macrophages. However, no definite information is available on the interaction among β2GPI, LPS and endothelial TLR4 in spite of the main role of endothelial cells (EC) in clotting. To analyse at the endothelial level the need of LPS, we investigated the in vitro interaction of β2GPI with endothelial TLR4 and we assessed the role of LPS in such an interaction. To do this, we evaluated the direct binding and internalization of β2GPI by confocal microscopy in living TLR4-MD2 transfected CHO cells (CHO/TLR4-MD2) and β2GPI binding to CHO/TLR4-MD2 cells and human umbilical cord vein EC (HUVEC) by flow cytometry and cell-ELISA using anti-β2GPI monoclonal antibodies in the absence or presence of various concentrations of exogenous LPS. To further investigate the role of TLR4, we performed anti-β2GPI antibody binding and adhesion molecule up-regulation in TLR4-silenced HUVEC. Confocal microscopy studies show that β2GPI does interact with TLR4 at the cell membrane and is internalized in cytoplasmic granules in CHO/TLR4-MD2 cells. β2GPI binding to CHO/TLR4-MD2 cells and HUVEC is also confirmed by flow cytometry and cell-ELISA, respectively. The interaction between β2GPI and TLR4 is confirmed by the reduction of anti-β2GPI antibody binding and by the up-regulation of E-selectin or ICAM-1 by TLR4 silencing in HUVEC. β2GPI binding is not affected by LPS at concentrations comparable to those found in both β2GPI and antibody preparations. Only higher amount of LPS that can activate EC and up-regulate TLR4 expression are found to increase the binding. Our findings demonstrate that β2GPI interacts directly with TLR4 expressed on EC, and that such interaction may contribute to β2GPI-dependent aPL-mediated EC activation. At variance of monocytic cells, we also showed a threshold effect for the action of LPS, that is able to enhance anti-β2GPI antibody EC binding only at cell activating concentrations, shown to increase TLR4 expression. This in vitro model may explain why LPS behaves as a second hit increasing the expression of β2GPI in vascular tissues and triggering aPL-mediated thrombosis in experimental animals.
Collapse
Affiliation(s)
- Elena Raschi
- Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy
| | - Cecilia B Chighizola
- Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Claudia Grossi
- Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy
| | - Nicoletta Ronda
- Department of Applied Pharmacological, Biological and Chemical Sciences, University of Parma, Parma, Italy
| | - Rita Gatti
- Department of Experimental Medicine, University of Parma, Parma, Italy
| | - Pier Luigi Meroni
- Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
| | - M Orietta Borghi
- Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| |
Collapse
|
3
|
A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 123:3478-87. [PMID: 24642748 DOI: 10.1182/blood-2013-11-537704] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A single-chain fragment variable (scFv) recognizing β2-glycoprotein 1 (β2GPI) from humans and other species was isolated from a human phage display library and engineered to contain an IgG1 hinge-CH2-CH3 domain. The scFv-Fc directed against β2GPI domain I-induced thrombosis and fetal loss, thus mimicking the effect of antibodies from patients with antiphospholipid syndrome (APS). Complement is involved in the biological effect of anti-β2GPI scFv-Fc, as demonstrated by its ability to promote in vitro and in vivo complement deposition and the failure to induce vascular thrombosis in C6-deficient rats and fetal loss in C5-depleted mice. A critical role for complement was also supported by the inability of the CH2-deleted scFv-Fc to cause vessel occlusion and pregnancy failure. This antibody prevented the pathological effects of anti-β2GPI antibodies from APS patients and displaced β2GPI-bound patient antibodies. The CH2-deleted antibody represents an innovative approach potentially useful to treat APS patients refractory to standard therapy.
Collapse
|
4
|
Martínez-Flores JA, Serrano M, Alfaro J, Mora S, Paz-Artal E, Morales JM, Serrano A. Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Anal Chem 2013; 85:12093-8. [PMID: 24245938 DOI: 10.1021/ac403194t] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
IgA antibeta 2 Glycoprotein I (β2GPI) antibodies test can identify some patients with antiphospholipid syndrome (APS) that are negative for other isotypes. Controversy exists because some studies have reported a strong association of these antibodies with vascular disease, while others have not confirmed this observation. Our hypothesis is that these contradictory results may be due to differences among commercial diagnostic kits. To answer this question, we have compared the results obtained with several of the most commonly used commercial IgA anti β2GPI antibodies (aβ2GPI) diagnostic assays on specimens from individuals suspected of having APS. Sera from 69 patients (37 positive and 32 negative for IgA aβ2GPI) were analyzed with seven different commercial ELISA kits for IgA aβ2GPI, following instructions and cutoffs provided by the manufacturer. Our results showed important differences in the sensitivity and specificity of the different assays. Two of the seven kits tested had a sensitivity level below 65% for IgA aβ2GPI, and three showed levels of specificity lower than 80%. Some commercial kits to detect IgA aβ2GPI are suboptimal. Variability between kits may account for the discrepancy in results obtained and for the lack of consensus concerning their clinical significance. It is important that the scientific community work to standardize assay performance so that the true clinical significance of this important clinical marker can be clearly established.
Collapse
Affiliation(s)
- José A Martínez-Flores
- Department of Immunology and ‡Department of Nephrology, Instituto de Investigación Hospital Universitario , 12 de Octubre, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
The updated international consensus criteria for definite antiphospholipid syndrome (APS)
are useful for scientific clinical studies. However, there remains a need for diagnostic
criteria for routine clinical use. We audited the results of routine antiphospholipid
antibodies (aPLs) in a cohort of 193 consecutive patients with aPL positivity-based
testing for lupus anticoagulant (LA), IgG and IgM anticardiolipin (aCL) and
anti-ß2glycoprotein-1 antibodies (aß2GPI). Medium/high-titre
aCL/aβ2GPI was defined as >99th percentile. Low-titre
aCL/aβ2GPI positivity (>95th < 99th percentile) was
considered positive for obstetric but not for thrombotic APS. One hundred of the 145
patients fulfilled both clinical and laboratory criteria for definite APS. Twenty-six
women with purely obstetric APS had persistent low-titre aCL and/or aβ2GPI.
With the inclusion of these patients, 126 of the 145 patients were considered to have APS.
Sixty-seven out of 126 patients were LA-negative, of whom 12 had aCL only, 37 had
aβ2GPI only and 18 positive were for both. The omission of aCL or
aβ2GPI testing from investigation of APS would have led to a failure to
diagnose APS in 9.5% and 29.4% of patients, respectively. Our data suggest that LA, aCL
and aβ2GPI testing are all required for the accurate diagnosis of APS and that
low-titre antibodies should be included in the diagnosis of obstetric APS.
Collapse
Affiliation(s)
- C Gardiner
- Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
| | | | | | | |
Collapse
|
6
|
Abstract
Abstract
In vitro studies have documented β2 glycoprotein I (β2GPI) binding to endothelial cells (ECs) and trophoblast using antiphospholipid antibodies. The in vivo binding of β2GPI to these cells and the conditions that favor their interaction have not been investigated. We analyzed the in vivo distribution of cyanine 5.5-labeled β2GPI in mice and evaluated the effect of pregnancy and circulating antibodies on its tissue localization. The signal was detected in the liver by whole body scan and ex vivo analysis. The β2GPI failed to bind to the vascular endothelium and reacted only with the ECs of uterine vessels. In pregnant mice the protein was localized on ECs and trophoblast at the embryo implantation sites. Immunized mice showed a similar β2GPI biodistribution to naive mice but the immunized pregnant animals exhibited a significant increase in fetal loss associated with C3 and C9 deposition at the implantation sites. Treatment of mice with LPS after β2GPI-Cy5.5 injection promoted protein localization on gut and brain ECs associated with IgG, C1q, and C9 deposition in immunized mice. These findings indicate that β2GPI binding to EC requires priming with pro-inflammatory factors which is not needed for uterine and placental localization probably dependent on hormonal changes.
Collapse
|
7
|
Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270:110-22. [PMID: 21323768 DOI: 10.1111/j.1365-2796.2011.02362.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12 weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β(2) -glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.
Collapse
Affiliation(s)
- A Tripodi
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, IRCCS Cà Granda Ospedale Maggiore Policlinico Foundation and Università degli Studi di Milano, Milan, Italy.
| | | | | |
Collapse
|
8
|
Müller C, Schlichtiger A, Balling G, Steigerwald U, Luppa PB, Thaler M. Standardized antigen preparation to achieve comparability of anti-beta2-glycoprotein I assays. Thromb Res 2010; 126:e102-9. [PMID: 20659619 DOI: 10.1016/j.thromres.2010.05.022] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2010] [Revised: 04/29/2010] [Accepted: 05/20/2010] [Indexed: 10/19/2022]
Abstract
INTRODUCTION The Sydney classification for diagnosis of the antiphospholipid syndrome (APS) first introduced the determination of anti-beta2-glycoprotein I (anti-beta2-GPI)-antibodies in serum as laboratory criteria. In this context, widely differing results of anti-beta2-GPI assays are a concerning issue. Considerable efforts have been made to optimize ELISAs, however little attention was hitherto spent to the antigen preparation. We evaluated the influence of different beta2-GPI preparations on the ability to separate ill and healthy patients and on the comparability of anti-beta2-GPI-assays. MATERIALS AND METHODS Microplates were coated with various beta2-GPI preparations and anti-beta2-GPI IgG- and IgM-ELISAs were performed for 21 APS patients and 21 controls using the monoclonal calibrators HCAL and EY2C9. Subsequently, by use of a surface plasmon resonance (SPR) biosensor, affinity constants for the HCAL- and EY2C9-interaction with each beta2-GPI preparation were determined and antigen binding of sera of APS patients and controls was studied. RESULTS All ss2-GPI preparations showed good discrimination ability ill vs. healthy but poor inter-assay comparability in the ELISAs. Affinity constants for HCAL and EY2C9 were independent of the beta2-GPI variant (K(A) 0.105 - 0.200 and 0.449 - 1.04 x 10(10)M(-1); K(D) 50.0 - 95.5 and 9.61 - 22.3 x 10(-11)M, respectively). In the biosensor, reactivity to the different beta2-GPIs was negligible for the controls and varied considerably for patients. CONCLUSION Inter-assay comparability of anti-beta2-GPI ELISAs is highly dependent upon the beta2-GPI preparation. Only agreement on one common beta2-GPI preparation will improve the requested inter-assay comparability.
Collapse
Affiliation(s)
- Carolin Müller
- Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, D-81675 München, Germany
| | | | | | | | | | | |
Collapse
|